Biotech Investing New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
Biotech Investing Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040
Biotech Investing Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
Biotech Investing Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027
Biotech Investing Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027
Biotech Investing Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference
Biotech Investing Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders
Biotech Investing Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT
biotech investing Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis
Forge Resources Intersects 3.4 g/t Gold over 44.75 Metres, and 800 Metre Step-Out Discovers 1.04 g/t Gold over 55.52 Metres at Alotta, Yukon
Element79 Gold Corp Files NI 43-101 Technical Report for Elephant Project in Nevada's Battle Mountain District
